Loading
A phase 1 trial of CB-011 run by Caribou Biosciences, Inc., now recruiting.
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT05722418 by Caribou Biosciences, Inc., with 50 participants planned, started 2023-02-06. Conditions recorded: Relapsed/Refractory Multiple Myeloma. Interventions recorded: CB-011.
Shares Caribou Biosciences and the tag pipeline.
Shares Caribou Biosciences and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/